Clinical Trials
9 trialsNCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03504397 2026-05-04
Spotlight
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT03653507 2026-04-17
GLOW
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT02864992 2026-04-13
VISION
EMD Serono
Phase 2 Active not recruiting
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT03329690 2022-03-18
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
Daiichi Sankyo
Phase 2 Completed
NCT02737501 2021-08-20
ALTA-1L
Takeda
Phase 3 Completed
NCT01121393 2018-12-14
BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
Boehringer Ingelheim
Phase 3 Completed
NCT00949650 2018-04-06
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Boehringer Ingelheim
Phase 3 Completed